The Human Connectome Project (HCP), part of the National Institutes of Health (NIH), recently announced that its new software has mapped 180 specific regions within the brain’s cortex automatically, more than doubling the previous number.
Leaders at AbbVie, a worldwide biopharmaceutical company, recently announced that it has launched its phase-three clinical trial concerning venetoclax, which is designed to treat patients who have relapsed or refractory multiple myeloma.
Officials with the U.S. Food and Drug Administration recently granted approval of Adlyxin (lixisenatide), which is designed to be used with diet and exercise to improve glycemic control, or blood sugar levels, in type 2 diabetes patients.
Leaders with the U.S. Food and Drug Administration recently released a proposed rule to ask for more scientific data to support the efficacy and safety of various active ingredients that are added to hand sanitizers.
Merck, called MSD outside of Canada and the U.S., recently announced that its new Keytruda (pembrolizumab) treatment for advanced or metastatic non-small cell lung cancer (NSCLC) has gained approval from the European Commission (EC).
The ALS Association and Cytokinetics Inc. recently announced that they have chosen to continue and broaden their current partnership against ALS, furthering their support of various initiatives and programs.
The ALS Association, LAS Finding a Cure and Massachusetts General Hospital recently invested approximately $3.6 million to broaden the NeuroBANK program, which offers core and infrastructure services to ALS research communities.
A recent study from the 'Journal of the American Heart Association' shows that just before menopause there is a greater severity for metabolic syndrome, as well as risk factors for stroke, heart attack and diabetes.
State Rep. Adam Kinzinger (R-IL) recently took note of the skills that military veteran medics have in the health industry and developed a solution to help these veterans as they look for work as civilians.
A team of scientists from the National Institutes of Health (NIH) recently found the genetic mutation that causes a rare kind of pediatric progressive neuropathy -- and they may have developed a therapeutic target to treat the disease.
The Partnership to Fight Chronic Disease (PFCD) recently launched the Federal Communications Commission’s (FCC’s) Connect2Health Task Force (C2H), which is dedicated to the new Mapping Broadband Health in America technology.